Estriol and Cognition in Multiple Sclerosis

Estriol and Cognition in Multiple Sclerosis
Recruiting
18 years - 55 years
Female
Phase 2
1 Location

Brief description of study

The purpose of this study is to determine whether the combination of treatment with available MS therpies and estriol has an effect on cognitive function and disease activity and outcomes.

Detailed description of study

Eligible participants include women with all forms of Multiple Sclerosis on a stable dose of FDA approved MS therapy for 90 days or more. Patients may be off MS therapy, but also for 90 days or more and medically stable. Participants must be able to walk 330 feet without rest (unilateral assistance, such as a cane is allowed). Males are not eligible to participate.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Multiple sclerosis,Chronic Progressive Multiple Sclerosis,RRMS,Relapsing-Remitting Multiple Sclerosis,SPMS,PPMS
  • Age: 18 years - 55 years
  • Gender: Female


Updated on 19 Feb 2024. Study ID: 817675

Find a site

Message sent successfully.
We have submitted the information you provided to the research team at the location you chose. For your records, we have sent a copy of the message to your email address.
If you would like to be informed of other studies that may be of interest to you, you may sign up for Patient Notification Service.
Sign up

Send a message

Enter your contact details to connect with study team

Email

View email

Phone

Phone country flag

View phone
Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact
Race
Ethnicity
Other language

Message For Non Enrolling By Invitation Trial

Select a study center that’s convenient for you, and get in touch with the study team.